Inactive Instrument

Highlights Nanoform Finland Oyj Nasdaq Helsinki

Equities

FI4000330972

Highlights

Unlock all the news: Be the first to know and act before the market!

Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024	30/05	CI
Nanoform Finland to Deliver Nanomedicine Technology to Japan	11/04	MT
Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	11/04	CI
Nanoform Teams Up with PlusVitech to Repurpose Anti-Nausea Drug for Lung Cancer Treatment	09/04	MT
Nanoform Finland plc and Plusvitech Partner to Repurpose Aprepitant as A Treatment for Lung Cancer	09/04	CI
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Nanoform Finland Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02	CI
Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation	29/02	CI
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide	26/01	CI
Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide	05/01	CI
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	22/11	CI
Nanoform Finland Signs Licensing Deal for AI Technology with AstraZeneca	23/23/23	MT
Nanoform Grant Global STARMAP[®] AI License to AstraZeneca	23/23/23	CI
Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/23/24	CI
Finland’s Nanoform, Celanese to Advance Partnership in Nanoparticle-enabled Drug Delivery Study	15/23/15	MT
Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants	15/23/15	CI
Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate	09/23/09	CI
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29/22/29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nanoform Finland Oyj Nasdaq Helsinki

Equities

FI4000330972

Highlights

Filters